Metformin hydrochloride (HCl), a well-known drug approved by the U.S. Food and Drug Administration (FDA), is primarily recognized for its role in treating type 2 diabetes. However, recent clinical trials and studies have highlighted its potential in addressing age-related processes, marking a significant development in healthcare.
Metformin and Longevity
A groundbreaking study involving over 100,000 patients revealed that individuals with type 2 diabetes treated with metformin HCl showed a longer life expectancy compared to nondiabetic control subjects, and even more so than diabetic patients on other anti-diabetes drugs. This discovery opens new avenues in understanding the impact of metformin beyond its conventional use.
Mechanisms of Action
Metformin’s potential in anti-aging can be attributed to several key mechanisms:
- Insulin and IGF-1 Signaling: It helps in decreasing insulin levels, thereby reducing the associated signaling pathways.
- mTOR Inhibition: Metformin is known to inhibit mTOR, a pathway linked to aging and cellular growth.
- Mitochondrial Function: It impacts mitochondrial complex 1 in the electron transport chain, reducing reactive oxygen species generation.
- AMP-activated Kinase Activation: AMPK, crucial for cellular energy homeostasis, is activated by metformin.
- Inflammation and Autophagy: The drug plays a role in reducing inflammation and promoting autophagy, both important in aging.
- Cellular Senescence and DNA Damage: It also contributes to the reduction of cellular aging and DNA damage.
Metformin and Weight Management
Interestingly, metformin’s effect on AMPK could also aid in weight loss. It helps reduce the glycemic index and food intake, vital for weight management. Additionally, it influences the hypothalamic-pituitary axis, affecting leptin and insulin sensitivity and regulating fat oxidation and deposition.
Challenges and Innovations
Despite its benefits, oral metformin HCl faces challenges like gastrointestinal side-effects, rapid metabolism, patient non-compliance, potential hypoglycemia, and low intestinal bioavailability. These factors necessitate exploring new delivery methods.
Transdermal Delivery: A New Frontier
A recent study in the International Journal of Pharmaceutical Compounding explored transdermal delivery of metformin HCl using a semisolid vehicle, Pentravan®. This method showed promising results, with a steady-state metformin flux through the skin and a permeation percentage close to oral bioavailability. This could potentially avoid the side-effects associated with oral delivery, making it a viable alternative for anti-aging, anti-obesity, and other clinical applications.
Metformin HCl, traditionally known for its role in diabetes management, is proving to be a versatile drug with potential applications in anti-aging and weight management. Its multifaceted benefits, coupled with ongoing research into alternative delivery systems like transdermal routes using Pentravan®, highlight its significance in modern medicine. For healthcare professionals and the general audience interested in healthcare advancements, metformin HCl remains a subject of great interest and potential.
References:
Ahad A, Al-Saleh AA, Akhtar N, Al-Mohizea AM, Al-Jenoubi FI. Transdermal delivery of antidiabetic drugs: formulation and delivery strategies. Drug Discov Today. Published online 2015. doi:10.1016/j.drudis.2015.06.002
Algire C, Moiseeva O, Deschênes-Simard X, et al. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res. Published online 2012. doi:10.1158/1940-6207.CAPR-11-0536
Allena RT, Yadav HKS, Sandina S, Sarat Chandra Prasad M. Preparation and evaluation of transdermal patches of metformin hydrochloride using natural polymer for sustained release. Int J Pharm Pharm Sci. Published online 2012.
Bannister C a, Holden SE, Morgan CL, Halcox JP, Schernthaner G. Can people with type 2 diabetes live longer than those without? Sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes, Obes Metab. Published online 2014. doi:10.1111/dom.12354
Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a Tool to Target Aging. Cell Metab. Published online 2016. doi:10.1016/j.cmet.2016.05.011
Bridges HR, Jones AJY, Pollak MN, Hirst J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J. Published online 2014. doi:10.1042/BJ20140620
Bulterijs S. Metformin as a geroprotector. In: Rejuvenation Research. 2011. doi:10.1089/rej.2011.1153
Cho K, Chung JY, Cho SK, et al. Antihyperglycemic mechanism of metformin occurs via the AMPK/LXRα/POMC pathway. Sci Rep. Published online 2015. doi:10.1038/srep08145
Das A, Ghosh S, Das S, Dey BK, Ghosh TK. Formulation and in vitro evaluation of transdermal patches of metformin hydrochloride using hydrophilic and hydrophobic polymer complex. Res J Pharm Technol. Published online 2011.
Igel LI, Sinha A, Saunders KH, Apovian CM, Vojta D, Aronne LJ. Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity. Curr Atheroscler Rep. Published online 2016. doi:10.1007/s11883-016-0568-3
Jadhav KS, Dungan CM, Williamson DL. Metformin limits ceramide-induced senescence in C2C12 myoblasts. Mech Ageing Dev. Published online 2013. doi:10.1016/j.mad.2013.11.002
Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of ErbB2/IGF-1 receptor interactions. Cell Cycle. Published online 2011. doi:10.4161/cc.10.17.16359
Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes. Published online 2014. doi:10.1097/MED.0000000000000095
Nair V, Sreevalsan S, Basha R, et al. Mechanism of Metformin-dependent Inhibition of Mammalian Target of Rapamycin (mTOR) and Ras Activity in Pancreatic Cancer: role of specificity protein (Sp) transcription factors. J Biol Chem. Published online 2014. doi:10.1074/jbc.M114.592576
Novelle MG, Ali A, Diéguez C, Bernier M, de Cabo R. Metformin: A hopeful promise in aging research. Cold Spring Harb Perspect Med. Published online 2016. doi:10.1101/cshperspect.a025932
Pérez-Revuelta BI, Hettich MM, Ciociaro A, et al. Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation. Cell Death Dis. Published online 2014. doi:10.1038/cddis.2014.175
Polonini H, Cândido PJL, Andrade JL, et al. Transdermal Delivery of Metformin Hydrochloride from a Semisolid Vehicle. Int J Pharm Compd. Published online 2019.
Saisho Y. Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect. Endocrine, Metab Immune Disord Targets. Published online 2015. doi:10.2174/1871530315666150316124019
Sharma RK, Sharma N, Rana S, Shivkumar HG. Solid lipid nanoparticles as a carrier of metformin for transdermal delivery. Int J Drug Deliv. Published online 2013. doi:10.5138/ijdd.v5i2.1009
Shaheen SM, Jahan L, Ferdaus R. A therapeutic TDS patch of metformin from a HPMC-PVA blend studied with a biological membrane of fish-swim bladder: An approach for dermal application in NIDDM. Pak J Pharm Sci. Published online 2015.
Song YM, Lee YH, Kim JW, et al. Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway. Autophagy. Published online 2015. doi:10.4161/15548627.2014.984271
